Skip to main content
OpenTrials
Completed

NCT Number: NCT04884516

Study To Investigate If Embody's Retinol Gummies Improve The Early Signs Of Skin Aging And Overall Skin Health

The Embody retinol study is a single-arm clinical trial on skin aging prevention and adult acne. The purpose of this study is to determine the effect of a retinol gummy in adults aged 18-45 on skin aging and overall skin health.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Santa Monica, California, 90404, United States

About this study

Embody has developed a retinol gummy with the aim to improve the appearance of early signs of aging, such as fine lines, dark spots, and sagging. Embody's retinol gummy has also the goal to reduce the overall frequency of adult acne and an improvement of overall skin health by promoting hydrated, brightened skin. The study aims to collect self-reported outcomes and photographic images to understand the assessment of the efficacy of treatment from the participant's perspective, and if participants see an improvement in their fine lines, wrinkles, dark spots, and sagging.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female between 18-45 years old
  • Must be in good general health
  • May experiences adult acne and/or early-stage wrinkles that are not treated by topical or oral prescription drugs/medication
  • Must maintain a basic skincare routine
  • Must discontinue the use of other dietary supplements
  • Must be willing to comply with the requirements of the protocol
  • Is able to communicate in English
  • Is willing to skip their normal skincare routine
  • Must provide written informed consent form (ICF)
  • Is willing and able to share feedback and take skin pictures via the used technology portal

Exclusion criteria

  • Unwilling to provide consent
  • Unwilling to skip their normal skincare routine
  • Unwilling to follow the routine of the protocol
  • Use of other oral retinoids
  • Use of prescription medication relevant to the skin
  • Undergoing any cosmetic procedures during the study including Botox, laser or chemical treatments
  • Deep-set of wrinkles
  • History of the following medical conditions or diseases:
  • Kidney disease
  • Liver disease
  • Alcohol abuse
  • Use of prescription drug (topical or oral) that is targeted at any sort of skin condition (for example retinoids)
  • Any known allergies/sensitivities to nuts

Treatment and study plan

Retinol gummy

Dietary Supplement

Participants take one retinol gummy per day

Primary outcomes

  1. Skin aging [Time frame: Baseline to 8 weeks]

    Time frame: 8 week intervention period

    Patient reported outcome measures (Scale 0-5 with higher scores representing a better outcome) to assess the reduction of early signs of aging such as fine lines, dark spots, and sagging

  2. Adult acne [Time frame: Baseline to 8 weeks]

    Time frame: 8 week intervention period

    Reduction the overall frequency and intensity of adult acne (Scale 0-5 with higher scores representing a reduction in the appearance of adult acne)

Sponsors and collaborators

Lead sponsor

Embody Beauty, Inc.

Industry

Collaborators

  • Citruslabs

Registry information

Official study title

Study to Identify if Embody's Retinol Gummy Works to Improve the Appearance of Early Signs of Aging and to Examine if it Reduces the Overall Frequency and Intensity of Adult Acne.

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
May 13, 2021
Registry last updated
May 13, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.